NCT05146843

The Impact of Chronic Mitochondrial Antioxidant Supplementation on CardiovascularToxicity in Breast Cancer Patients

Status unknown NA Last updated 8 April 2022

What this trial tests

NA trial testing Mitoquinone in Breast Neoplasms in 44 participants. Status unknown.

Timeline

2 June 2022

Primary endpoint
1 November 2022

2 December 2023

Quick facts

Lead sponsor	D'Or Institute for Research and Education
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	44
Start date	2 June 2022
Primary completion	1 November 2022
Estimated completion	2 December 2023

Drugs / interventions tested

• Mitoquinone — full drug profile →
• Placebo

Conditions studied

• Breast Neoplasms — all drugs for Breast Neoplasms →

Sponsor

D'Or Institute for Research and Education

Who can join

Adults 18 to 75, any sex, with Breast Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigate the protective effect of chronic MitoQ supplementation on cardiovascular toxicity induced by doxorubicin-based adjuvant chemotherapy in breast cancer patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Oxidative stress in cancer: from tumor and microenvironment remodeling to therapeutic frontiers.
   Liang X, Weng J, You Z, Wang Y, et al · · 2025 · cited 50× · PMID 40847302 · DOI 10.1186/s12943-025-02375-x
2. Mitochondrial metabolism and cancer therapeutic innovation.
   Du H, Xu T, Yu S, Wu S, et al · · 2025 · cited 43× · PMID 40754534 · DOI 10.1038/s41392-025-02311-x
3. Multifaceted functions of Drp1 in hypoxia/ischemia-induced mitochondrial quality imbalance: from regulatory mechanism to targeted therapeutic strategy.
   Hao S, Huang H, Ma RY, Zeng X, et al · · 2023 · cited 28× · PMID 37833768 · DOI 10.1186/s40779-023-00482-8
4. Role of mitochondria in physiological activities, diseases, and therapy.
   Wang L, Zhou X, Lu T. · · 2025 · cited 23× · PMID 40536597 · DOI 10.1186/s43556-025-00284-5
5. Persistent accumulation of therapy-induced senescent cells: an obstacle to long-term cancer treatment efficacy.
   Luo J, Sun T, Liu Z, Liu Y, et al · · 2025 · cited 10× · PMID 40750580 · DOI 10.1038/s41368-025-00380-w
6. A bench to bedside perspective on anthracycline chemotherapy-mediated cardiovascular dysfunction: challenges and opportunities. A symposium review.
   Clayton ZS, Ade CJ, Dieli-Conwright CM, Mathelier HM. · · 2022 · cited 5× · PMID 36302155 · DOI 10.1152/japplphysiol.00471.2022
7. Kinase signalling adaptation supports dysfunctional mitochondria in disease.
   Skalka GL, Tsakovska M, Murphy DJ. · · 2024 · cited 4× · PMID 38434478 · DOI 10.3389/fmolb.2024.1354682
8. Anthracycline chemotherapy, vascular dysfunction and cognitive impairment: burgeoning topics and future directions.
   Maurer GS, Clayton ZS. · · 2023 · cited 4× · PMID 36354315 · DOI 10.2217/fca-2022-0086